Ascentage Pharma Group International
ASPHF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.4B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.40 Billion |
|---|---|
| Enterprise Value | $1.67 Billion |
| Earnings per Share | $-3.43 |
| Beta | 0.61 |
| Outstanding Shares | 373,248,217 |
Return
| Return on Equity | -376.72% |
|---|---|
| Return on Assets | -64.68% |
| Return on Invested Capital | -145.83% |
Valuation & Multiples
| P/E Ratio | -6.63 |
|---|---|
| PEG | -0.74 |
| Price to Sales | 1.88 |
| Price to Book Ratio | 3.75 |
| Enterprise Value to Revenue | 2.03 |
| Enterprise Value to EBIT | -0.84 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.3 |
| Debt to Equity | 3.89 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
$53.85 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$50.08 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ascentage Pharma Group International
828 employees
CEO: Dajun Yang
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations...